They found that the proximal PolyA selection of CARM1, through loss of miRNA binding, upregulates CARM1's EMT inducers and releases miRNAs that downregulate the EMT inhibitor RBM47, serving as a pathological biomarker for mesenchymal tumours and tumour metastasis. The gene discussed is CARM1; the disease is neoplasm.